What were the key takeaways from Ligand’s earnings call?

What is Ligand's gross profit margin?

Did Ligand beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Ligand year over year?

What does Ligand do and what are its main business segments?

What factors drove the changes in Ligand's revenue and profit?

What were the key takeaways from Ligand's earnings call?

What guidance did Ligand's management provide for the next earnings period?

- **Exceptional 2025 Performance**: Adjusted EPS up 42% to $8.13, royalty revenue +48%. 2026 guidance: EPS $8-$9M, royalty $200-$225M.
- **High-Growth Pipeline**: 23% CAGR 2026-2030, driven by FILSPARI, Ohtuvayre, and 5+ late-stage assets.
- **Strategic Capital Deployment**: $1B+ to invest in high-impact royalty streams, including QTORIN ($100M-$300M peak) and lasofoxifene ($80M+).
- **Portfolio Management**: Proactive engagement with 5-10 assets, e.g., LeonaBio partnership for Phase 3 breast cancer drug.
- **Market Leadership**: Leading in biopharma royalty financing with $1B+ deployable capital, doubling market share in 5 years.

**【CEO Summary Section】**
- **2025 Financial Success**: Full-year adjusted EPS exceeded guidance by 30%, driven by 48% growth in royalty revenue. Key contributors included FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI.
- **Future Growth Strategy**: $1 billion deployable capital to pursue high-impact investments. 2026-2030 royalty CAGR of 23%, with 15% from commercial programs and 5% from development-stage assets.
- **Strategic Initiatives**: Expanded business development team, systematic portfolio management, and focus on royalty financing as a strategic capital tool.

**【CFO Financial Commentary】**
- **2025 Financials**: Total GAAP revenue $268M (43% YoY core growth). Adjusted EPS $8.13 (42% YoY). Q4 royalty revenue $50.5M (45% YoY).
- **2026 Guidance**: Adjusted EPS $8-$9M, royalty revenue $200-$225M. FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI expected to drive growth.
- **Balance Sheet Strength**: $734M cash, $1B+ deployable capital post-Pelthos spin-off.

**【Portfolio Strategy Update】**
- **Lasofoxifene**: Phase 3 ELAINE trial >50% enrolled, potential $80M annual royalties at $1B peak sales.
- **Palvella's QTORIN**: Phase 3 mLM success, NDA submission H2 2026. cVM Phase 2 positive, $100M-$300M peak royalties.
- **FILSPARI**: U.S. FSGS approval delayed, but Japan NDA expected. 9% royalty on $1B+ peak sales per indication.
- **Ohtuvayre**: $500M+ 2025 sales, China NDA filed. CAPVAXIVE nearing blockbuster status.

**【Q&A Highlights】**
- **Clinical Catalysts**: 10+ late-stage assets with 2026 readouts (e.g., lasofoxifene, Tzield T1D, BOT/BAL).
- **Asset Monetization**: 5-10 active portfolio management opportunities, e.g., LeonaBio PIPE for lasofoxifene.
- **Market Dynamics**: Royalty financing market doubling in 5 years, strategic for biopharma despite equity market conditions.
- **FILSPARI Impact**: 2026 FSGS royalty contribution ~$4M (risk-adjusted), significant upside post-approval.


Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Royalty revenue up 47% YoY, driven by Ohtuvayre (32% Q/Q), FILSPARI (26% Q/Q), and CAPVAXIVE ($244M sales). Full-year core revenue guidance raised to $225-$235M.
- **Strategic Investments**: $460M convertible debt financing and Q3 investments in Orchestra BioMed, Arecor, and Pelthos support 22% CAGR royalty growth target.
- **Financial Strength**: Adjusted EPS up 68% to $3.09, with $1B deployable capital and strong balance sheet ($665M cash).
- **Pipeline Momentum**: ZELSUVMI out-license gain ($24.5M), Phase II success for AT292, and FDA regulatory tailwinds (e.g., Commissioner's Voucher) highlight strategic execution.
- **Q&A Takeaways**: ZELSUVMI launch tracking ahead of expectations, Arecor deal leverages Sanofi's Phase II success, and limited competition in development-stage royalty investing.

**【CEO Summary Section】**
- **Revenue Growth and Strategic Moves**: CEO Todd Davis highlighted a 47% year-over-year increase in royalty revenue, driven by strong launches of Ohtuvayre, CAPVAXIVE, and FILSPARI. The company raised full-year guidance for core revenue to $225-$235 million and adjusted EPS to $7.40-$7.65, reflecting confidence in its portfolio. Ligand completed a $460 million convertible debt financing to support strategic investments.
- **Pipeline Momentum**: Key assets include Ohtuvayre (32% Q/Q sales growth), FILSPARI (26% Q/Q growth), and ZELSUVMI, which generated a $24.5 million out-license gain. The company expects a 22% CAGR for long-term royalty receipts, with existing assets contributing an 18% CAGR and new investments adding 4%+ upside.
- **Deal Activity**: Q3 investments included $35 million in Orchestra BioMed, $11 million in Arecor, and $5 million in Pelthos, supporting late-stage cardiology and rare disease programs. The deal pipeline remains robust, with 32 active opportunities under review.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net income was $117.3 million ($5.68 per share), while adjusted EPS rose 68% to $3.09. Core revenue grew 68% to $86.9 million, driven by royalty revenue ($46.6 million) and contract income ($53.1 million from Pelthos transaction). The balance sheet features $665 million in cash and $1 billion in deployable capital.
- **Key Drivers**: Royalty revenue from FILSPARI ($9 million Q3), Ohtuvayre ($136 million sales), and CAPVAXIVE ($244 million) contributed significantly. Operating expenses increased due to one-time charges (e.g., $17.8 million R&D investment in Orchestra BioMed), but adjusted margins remain strong.
- **Guidance Update**: Full-year 2025 core revenue guidance raised to $225-$235 million (vs. prior $200-$225 million), reflecting outperformance in key assets and the Pelthos transaction.

**【Q&A Highlights】**
- **ZELSUVMI Launch**: Pelthos reported strong early uptake, with peak sales guidance of $175 million. Ligand expects to benefit from Merck's global commercialization efforts post-Pelthos merger.
- **Arecor Transaction**: Ligand invested $11 million for technology access fees on Sanofi's AT292 (alpha-1 antitrypsin deficiency therapy), which met Phase II endpoints. The deal underscores Ligand's ability to capitalize on high-risk, high-reward opportunities.
- **Competitive Landscape**: CEO noted limited competition in development-stage royalty investing, with most capital focused on commercial assets. Ligand's focus on derisked, late-stage programs provides a competitive edge.
- **FDA Regulatory Shifts**: Positive trends like the Commissioner's National Priority Voucher program (e.g., TZIELD's accelerated review) align with Ligand's focus on high-clinical-need assets.


Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript

- **Revenue Growth Surges**: Royalty revenue up 57% YoY, adjusted EPS +14% to $1.60. Total revenue $47.6M (+15% YoY).
- **Strategic Wins**: $100M stake in Pelthos post-merger, $40M Orchestra BioMed investment with Breakthrough Devices.
- **O2vir Momentum**: Q2 sales $103M (+45% QoQ), Merck acquisition to accelerate $5B-$6B peak sales.
- **Guidance Upped**: 2025 core EPS $6.70-$7.00 (prev $6.00-$6.25), royalty $140M-$150M.
- **Pipeline Expansion**: 90+ assets, 25+ active deals, medical device diversification.

**【CEO Summary Section】**
- Royalty revenue grew 57% YoY to $36.4 million, driving a 14% increase in adjusted EPS to $1.60. Total revenue rose 15% to $47.6 million.
- Completed merger of Pelthos with Channel Therapeutics, resulting in a $100 million stake in Pelthos (NYSE: PTHS) after a 13-month investment. Zelsuvmi launch milestone of $5 million achieved.
- Invested $40 million in Orchestra BioMed's AVIM and Virtu SAB therapies, which received FDA Breakthrough Device Designations. Ligand earns high teens royalty on first $100M in revenues.
- O2vir (Verona) Q2 sales $103M, up 45% sequentially. Merck's $10B acquisition of Verona expected to accelerate global launch, with peak sales projections of $5B-$6B.
- Portfolio expansion includes 90+ assets, with focus on high clinical value, de-risked programs.

**【CFO Financial Commentary】**
- Full year 2025 guidance updated: Royalty revenue $140M-$150M (prev $135M-$140M), contract revenue $25M-$35M (prev $10M-$20M), core adjusted EPS $6.70-$7.00 (prev $6.00-$6.25).
- Key revenue drivers: O2vir (+45% QoQ), Filspari (IgA nephropathy sales growth), Qarziba (EUR 78.5M H1 sales), and CAPVAXIVE/Vaxneuvance (combined $358M Q2 sales).
- Operating expenses increased due to Pelthos incubation costs, but expect GAAP expenses to decline post-July 1 deconsolidation.
- Cash and investments: $245M, with $450M deployable capital (including $205M undrawn credit facility).

**【Q&A Highlights】**
- **Pelthos Launch Expectations**: Zelsuvmi targeting 100K+ patients in 16.7M Molluscum contagiosum market. Peak sales $175M, with Ligand earning $23M/year in royalties. Launch team experienced, but 2025 contribution minimal.
- **Filspari REMS Modification**: Quarterly monitoring for IgA nephropathy patients expected to boost uptake. FSGS PDUFA date Jan 13, 2026, with potential $1B+ sales if approved.
- **O2vir Tax Impact**: U.K. and Austrian tax rates (25% vs. 21% U.S. rate) diluting EPS. No interest in selling 3% royalty despite Merck's acquisition.
- **Pipeline Activity**: 25+ active investment opportunities, balanced between accretive and pre-approval deals. $40M Orchestra BioMed investment highlights medical device diversification.
- **Share Dilution**: Rising stock price increasing dilution impact on EPS. Focus on disciplined capital deployment to offset.

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: 46% total revenue increase to $45M, driven by 44% royalty growth.
- **Commercial Stars Perform**: Ohtuvayre ($71M Q1), Filspari ($56M Q1), Capvaxive ($107M Q1) exceed expectations.
- **$50M Zelsuvmi Deal**: Pelthos merger with Channel positions for 13% royalty on molluscum contagiosum treatment launch.
- **Strong Liquidity**: $209M cash, $400M deployable capital to fund 2025 investments.
- **Pipeline Expansion**: 38 active deals, targeting 22%+ CAGR through 2029.

**CEO Summary Section**
- Q1 2025 total revenue grew 46% YoY to $45 million, driven by 44% royalty revenue increase to $27.5 million.
- Key commercial assets: Verona’s Ohtuvayre (Q1 sales $71M, +100% QoQ), Travere’s Filspari (Q1 sales $56M, +180% YoY), Merck’s Capvaxive (Q1 sales $107M, +100% YoY).
- 10 new investments in 15 months, including $250M capital deployment, with focus on Phase 2/3 assets like D-Fi (Castle Creek partnership).
- Pelthos-Zelsuvmi merger with Channel Therapeutics secures $50M capital, targeting 13% royalty on molluscum contagiosum treatment launch Q3 2025.
- 2025 royalty revenue guidance: $135-140M, Captisol sales $35-40M, total revenue $180-200M.

**CFO Financial Commentary**
- Adjusted EPS $1.33 vs. $1.20 prior year, driven by royalty growth and Captisol restocking (Veklury sales $13.5M).
- Operating expenses: R&D $50M (+733% YoY) due to D-Fi Phase 3 investment, G&A $19M (+73% YoY) for Pelthos commercialization.
- Cash position: $209M (including $24M Viking Therapeutics equity), deployable capital $400M (cash + $125M credit facility).
- GAAP net loss $42.5M due to R&D charge, non-GAAP net income $26.6M.

**Q&A Highlights**
- Biopharma financing environment: Increased demand for royalty financing, 38 active deals pipeline (50% pre-approval, 50% accretive).
- Investment sizing: $50M max for binary risk deals (e.g., D-Fi), up to $100M for derisked assets (e.g., Apeiron).
- Zelsuvmi launch: Targeting 100,000+ patients, 13% royalty on $50M+ annual sales potential.
- Policy impact: MNF drug pricing may delay partner launches but U.S. remains primary market.
- Qarziba growth: Recordati expanding to Latin America, Ewing sarcoma indication in development.
- NITRICIL platform: Exploring partnerships for additional therapies beyond Zelsuvmi.

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

- **28% Revenue Growth**: 2024 royalty portfolio delivered $108.5M, up 28% YoY.
- **22%+ CAGR**: 2025-2029 royalty receipts expected to grow at 22%+ CAGR.
- **$50M Gene Therapy Investment**: D-Fi for DEB targets 3,000+ U.S. patients with no FDA-approved treatments.
- **$6-6.25 EPS Guidance**: 2025 adjusted EPS up 4-7% YoY, driven by expanding royalty base.
- **$256M Cash Position**: Strong balance sheet supports 2025+ deal flow.

**【CEO Opening Remarks】**
- 2024 revenue grew 28% YoY, core adjusted EPS rose 40% to $5.74, driven by strong royalty portfolio.
- Key commercial assets: Ohtuvayre (Verona Pharma), Capvaxive (Merck), Filspari (Travere) delivered record sales.
- 2025 royalty CAGR expected at 22%+, with pipeline investments adding 4%+ to growth.
- Operated with $256M cash, no debt, and $175M credit facility for future deals.

**【CFO Financial Highlights】**
- 2024 total revenue: $167.1M (27% YoY growth), royalty revenue: $108.5M (28% YoY).
- Q4 2024 royalty revenue: $34.8M (55% YoY), driven by Filspari (+40% QoQ) and Qarziba (Apeiron acquisition).
- 2025 guidance: Royalty $135-140M, Captisol $35-40M, contract $10-20M, EPS $6-6.25.
- 2025 operating expenses expected to grow ~4% YoY, aligning with inflation.

**【New Investment Update】**
- $50M royalty investment in Castle Creek's D-Fi gene therapy for DEB.
- D-Fi Phase 3 ready, targeting 3,000+ U.S. patients with no FDA-approved treatments.
- Mid-single-digit royalty on global sales, with potential to complement Krystal's Vyjuvek ($299M 2024 sales).

**【Q&A Key Takeaways】**
- D-Fi risk profile: De-risked with Phase 2/3 data, CMC validated, 75% partner co-investment.
- Captisol growth: SQ Innovation's Lasix launch (H2 2025) adds minor revenue, Gilead collaboration drives $35-40M 2025 sales.
- Strategic transactions: Pelthos Zelsuvmi launch (mid-2025) via partner, no plans for stock buybacks.
- Pipeline momentum: 12 commercial assets, 4 approvals in 2024, Filspari SNDA for FSGS (Q1 2025 submission).

Actual												0.5743	0.6453	0.6711	1.0454	0.9098	1.0518	1.0195	1.1615	0.3743	0.6646	0.2646	0.75	2.28	1.42	1.02	1.38	1.2	1.4	1.84	1.27	1.33	1.6	3.09	2.02
Forecast												0.4237	0.4904	0.6334	0.7034	0.7259	0.8914	0.6824	0.884	0.4227	0.2775	0.2788	0.7729	0.894	0.636	0.62	0.6608	0.834	1.0562	1.3471	1.19	1.2117	1.4214	1.9283	1.4971
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+35.54%	+31.59%	+5.95%	+48.62%	+25.33%	+17.99%	+49.40%	+31.39%	-11.45%	+139.50%	-5.09%	-2.96%	+155.03%	+123.27%	+64.52%	+108.84%	+43.88%	+32.55%	+36.59%	+6.72%	+9.76%	+12.57%	+60.24%	+34.93%

LGND

LGND fundamentals

LGND Q4 2025 Earnings

Earnings Call

You can ask Aime

LGND

LGND fundamentals

LGND Q4 2025 Earnings

Earnings Call

LGND Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

LGND Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

LGND Earnings Call Summary for Q2/20258:30 AM on Aug 7, 2025

LGND Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

LGND Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime